1. Home
  2. Live Updates
  3. India pharma market

Live Breaking News & Updates on India pharma market

Stay informed with the latest breaking news from India pharma market on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in India pharma market and stay connected to the pulse of your community

Chart of the Day: Sluggish volumes in domestic market should worry pharma investors

Volumes contributed just 0.7 percentage points of the 7.6 percent growth of Indian pharmaceutical market in FY24

India-pharma-market , Pm , Rowth , Olumes , Rice-hikes , Ew-products , Y24 , Usiness-growth , Nflation , Lowdown , Tocks

India's pharma market maintains 10% growth despite disruptions; set for 8-10% growth with price hikes, new launches, HDFC sec report

India's Pharma Market (IPM) maintains a solid ~10% CAGR from FY12 to FY23, facing disruptions but showing resilience.

India , Mehul-sheth , National-list-of-essential-medicines , Research-analyst , Services-tax , India-pharma-market , Compounded-annual-growth-rate , National-list , Essential-medicines , Fixed-dose-combination , Target-price ,

How fast-growing chronic drugs are reshaping the Indian pharma market

Pharma companies are increasing focus on chronic medicines as this category of drugs continues to outperform the Indian market

India-pharma-market , Hronic , Cute , Edicines-growth , Evenue , Ompanies , Ew-products , Pm , Tocks ,

Indian pharma's growth expectations are trending downwards

The market grew by just 3.5 percent in November 2023. Lower price hikes and competition from generics are the main obstacles to higher growth

India-pharma-market , Rowth , Rice-hikes , Ew-product-launches , Eneric-drugs , Ompetition , Arket-growth ,

Weak acute drug sales pose risk to Indian pharma's growth tempo

Growth in the Indian pharmaceutical industry slowed to 5.8 percent in August

India , India-pharma-market , Pm , Arket-mix , Rowth , Cute , Hronic , Nti-infectives , Lowdown , Harma-stocks , Aluations

JB Pharma celebrates 1 year to its identity launch, Delivers over 22 per cent growth for the fiscal

JB Pharma celebrates 1 year to its identity launch, Delivers over 22 per cent growth for the fiscal
aninews.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aninews.in Daily Mail and Mail on Sunday newspapers.

South-africa , Russia , United-states , India , Mumbai , Maharashtra , Nikhil-chopra , Swadeep-srivastava , Sidharth-ragnekar-shruti-joshi , Facebook , Heal-health , Indian-pharma-companies

JB Pharma celebrates 1 year to its identity launch, Delivers over 22 per cent growth for the fiscal

JB Pharma, the fastest growing company in the Indian Pharmaceutical Market, today marks the one-year anniversary of the launch of their identity. Good People fo

Russia , South-africa , United-states , India , Nikhil-chopra , Linkedin , Good-people-for-health , Contract-developmentmanufacturing-organisation , Facebook , Indian-pharma-companies , Indian-pharmaceutical-market , Good-health

JB Pharma celebrates 1 year to its identity launch, Delivers over 22 per cent growth for the fiscal

JB Pharma, the fastest growing company in the Indian Pharmaceutical Market, today marks the one-year anniversary of the launch of their identity. Good People fo

Russia , India , South-africa , United-states , Nikhil-chopra , Facebook , Good-people-for-health , Contract-developmentmanufacturing-organisation , Indian-pharma-companies , Linkedin , Indian-pharmaceutical-market , Good-health

Chart of the Day: India remains a bright spot for pharma companies

Amid the headwinds in North America, Indian pharma companies continues to see steady growth in India

India , Motilal-oswal-financial-services , Motilal-oswal-financial , Kotak-institutional , India-pharma-market , Rowth-trends , Pm , Upin , Ipla , R-reddy-s , Y23

Macquarie gives 'outperform' rating to Mankind Pharma, sees 30% upside

Brokerage firm Macquarie Research has given Mankind Pharma Ltd an outperform rating with a target price of Rs 1400 per share, indicating a potential upside of 29.6% from its issue price of Rs 1068 per share.

India , Mankind-pharma-ltd , Macquarie-research , Pfizer , Novartis , Mankind-pharma , India-pharma-market , Markets-news , Uzzing-stocks , Quity-markets , Ankind-pharma